Pharmaceuticals News and Research

RSS

Patient requests, drug company ties likely to influence doctors' decision to prescribe name-brand drugs

When patients ask for a brand-name drug, many physicians give in rather than prescribe a generic, according to a nationwide survey, and in-office promotions to doctors increase the likelihood.

9 Jan 2013

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801.

9 Jan 2013

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave (naltrexone SR / bupropion SR) New Drug Application (NDA).

9 Jan 2013

Researchers use electrokinetic patterning to separate particles and microbes by size

Researchers have demonstrated a new technology that combines a laser and electric fields to create tiny centrifuge-like whirlpools to separate particles and microbes by size, a potential lab-on-a-chip system for medicine and research.

9 Jan 2013

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.

8 Jan 2013

Groups urge HHS to issue rules on medical company-doc relationships

The American Medical Student Association and the National Physicians Alliance are urging the Obama Administration to issue past-due regulations for a database of payments made by pharmaceutical companies and device makers to physicians.

8 Jan 2013

Dementia diagnosis: an interview with Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition

Dementia is a huge public health problem, affecting about 800,000 people in the UK and 36 million people around the world.

8 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Industry sponsored drug and device studies: an interview with Professor Lisa Bero

Our review included analyses of drug and device studies conducted in humans. The drugs or devices could be compared to placebo or sham treatments, or other effective treatments. The drugs and devices examined for this review are used for a wide variety of clinical conditions, including cardiovascular and psychiatric diseases.

7 Jan 2013

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia."

7 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Research roundup: Gearing children's hospitals for future patients; Inappropriate care decreases, but not 'enough'; What patients think about testing

Researchers in this study examined the use of children's hospitals by relatively healthy children and those "with chronic conditions of varying medical complexity" from 2004 to 2009.

6 Jan 2013

ThromboGenics to launch JETREA in the U.S. on Jan. 14

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, confirms its JETREA US launch date of Monday January 14th, 2013.

4 Jan 2013

Thai health advocates work to protect special provisions on medicines under E.U. free trade agreement

Thailand and the European Union (E.U.) are expected to begin talks on a free trade agreement early this year, and Thai public health advocates have sent a letter to Joao Aguiar Machado, deputy director general for trade at the European Commission, "calling for the bloc to respect global trade rules' special provisions for developing countries," Inter Press Service reports.

4 Jan 2013

Scientists invent scalable method to make polyhydroxylated steroids

Scientists at The Scripps Research Institute (TSRI) have achieved a feat in synthetic chemistry by inventing a scalable method to make complex natural compounds known as "polyhydroxylated steroids." These compounds, used in heart-failure medications and other drugs, have been notoriously problematic to synthesize in the laboratory.

4 Jan 2013

Optofluidics allow for new understanding of resistance to antibiotics

It's often difficult to completely eliminate a bacterial infection with antibiotics; part of the population usually manages to survive. We've known about this phenomenon for quite some time, dating back nearly to the discovery of penicillin. For more than 50 years, scientists have believed that the resistant bacteria were individuals that had stopped growing and dividing.

4 Jan 2013

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

3 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).

3 Jan 2013

Pharmaceuticals News and Research

Patient requests, drug company ties likely to influence doctors' decision to prescribe name-brand drugs

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Researchers use electrokinetic patterning to separate particles and microbes by size

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Groups urge HHS to issue rules on medical company-doc relationships

Dementia diagnosis: an interview with Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Industry sponsored drug and device studies: an interview with Professor Lisa Bero

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

Research roundup: Gearing children's hospitals for future patients; Inappropriate care decreases, but not 'enough'; What patients think about testing

ThromboGenics to launch JETREA in the U.S. on Jan. 14

Thai health advocates work to protect special provisions on medicines under E.U. free trade agreement

Scientists invent scalable method to make polyhydroxylated steroids

Optofluidics allow for new understanding of resistance to antibiotics

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence